Zevra Q1 Revenue Soars 78% to $36.2M; Net Income Hits $37.9M
Zevra reported Q1 2026 net revenue of $36.2 million, a 78% increase year-over-year, and net income of $37.9 million versus a $3.1 million loss as MIPLYFFA sales reached $24.6 million. The company sold SDX portfolio for $50 million, prepaid $63.1 million term loan and ended debt-free with $236.8 million cash.
1. Q1 2026 Financial Performance
Zevra achieved net revenue of $36.2 million in Q1 2026, up 78% from $20.4 million a year earlier, driven by $24.6 million in MIPLYFFA sales, $0.3 million from OLPRUVA, $10.2 million in EAP reimbursements and $1.1 million in royalties. The company swung to net income of $37.9 million, or $0.62 per share, versus a $3.1 million loss in Q1 2025.
2. SDX Portfolio Sale and Debt Prepayment
During the quarter Zevra completed the $50.0 million sale of its SDX portfolio and applied $63.1 million to fully repay its term loan, eliminating debt. These actions bolstered its cash position to $236.8 million and strengthened financial flexibility.
3. MIPLYFFA Commercial and Regulatory Update
In the U.S., nine new MIPLYFFA prescription enrollment forms were received in Q1, bringing total enrollments to 170 with market access at 69% of covered lives. The EU Marketing Authorisation Application for arimoclomol is under EMA review with orphan designation, and 122 patients are enrolled in the global Expanded Access Program.
4. Phase 3 DiSCOVER Trial Progress
Zevra enrolled 10 patients in its event-driven Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome during Q1, reaching 62 total participants and recording two confirmed events. The company plans a follow-up meeting with the FDA in H2 2026 to explore accelerated development pathways.